In a report released yesterday, Yasmeen Rahimi from Piper Sandler initiated coverage with a Buy rating on Arcturus Therapeutics (ARCT – Research Report) and a price target of $140.00.
ARCT has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on ...
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $63.00. Ed Arce has given his Buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback